Cyclosporine Market – By Indication, By Dosage Form, By Route of Administration, By Distribution Channel & Global Forecast, 2025 – 2034

Report ID: GMI13069
   |
Published Date: January 2025
 | 
Report Format: PDF

Download Free PDF

Cyclosporine Market Size

The global cyclosporine market size was valued at USD 3.3 billion in 2024 and is estimated to grow at a CAGR of 14.5% from 2025 to 2034. In recent years, the sales of cyclosporine have specifically increased due to the growing demand for organ transplantation.
 

Cyclosporine Market

For instance, as per the data published by the National Institute of Health, around 46,632 organ transplants were completed in the year 2020 in the U.S., which reflects a growth of 12.7% from the previous year. Cyclosporine is in high demand in recent years as more and more organ transplant procedures are being performed. Thus, given the key role of cyclosporine in organ transplant patients, the cyclosporin market is anticipated to witness rapid growth in the future years.
 

Additionally, the growth of cyclosporine market has also been driven by increasing cases of autoimmune disorders such as rheumatoid arthritis. Cyclosporine helps treat the symptoms of arthritis but also decreases the progression of the condition thereby reducing the risk of long-term joint damage and disability. Furthermore, broadened access to health care in emerging countries coupled with an increase in investments in research and development focused on building new types of immunosuppressive therapies, further accelerates market growth.

Cyclosporine is an immunosuppression drug used to prevent organ rejection in transplant patients and has also found use in certain autoimmune disorders. It acts by inhibiting the normal activity of the T-lymphocytes that are central to the immune response. Kidney, liver, and heart transplant recipients are commonly treated with cyclosporine in order to decrease the likelihood of graft rejection.
 

Cyclosporine Market Trends

The growing prevalence of autoimmune diseases acts as a strong catalyst for the growth of the market.
 

  • According to the Institute for Health Metrics and Evaluation, in 2020, an estimated 17.6 million people around the world had rheumatoid arthritis. Also, psoriasis affects nearly 1-3% of the global population, corresponding to around 125 million individuals.
     
  • Autoimmune diseases such as rheumatoid arthritis and psoriasis occur as a result of the body’s abnormal response towards its healthy cells which results chronic inflammation and destruction of the affected tissues. The immunosuppressive drug, cyclosporine, is often prescribed for these conditions as it also alters immune activity reactions, helping to control the effect of over-reactive cells of the immune system.
     
  • Thus, as more people get autoimmune diseases, the demand for more effective treatment options like cyclosporine is in high demand.
     
  • In addition, increasing rate of new cases detection owing to advances in diagnostic techniques further exacerbates the need for effective therapies, thereby boosting the overall market growth.
     

Cyclosporine Market Analysis

Cyclosporine Market, By Indication, 2021 – 2034 (USD Billion)

Based on the indication, the global market is segmented into transplant rejection prophylaxis, rheumatoid arthritis, psoriasis, autoimmune myasthenia gravis, dry eye, and other indications. The transplant rejection prophylaxis segment dominated the market and was valued at USD 1.2 billion in 2024.
 

  • Transplant rejection has a large share of the cyclosporin market, mainly due to the importance of cyclosporin in preventing organ rejection in patients transplanted to receive an organ. Cyclosporin acts by inhibiting T-cell activation, which is a fundamental mechanism in the immune-mediated rejection of transplanted organs. It works by suppressing the immune system to prevent the white blood cells from trying to get rid of the transplanted organ.
     
  • The increasing number of organ transplant procedures, such as kidney, liver, and heart, have increased the need for cyclosporin for this use.
     
  • Moreover, its proven effectiveness and safety, as well as achieved clinical outcomes, make it the preferred option among doctors for the purposes of graft maintenance and increasing the survival of patients.
     
  • The increased awareness of organ transplantation and the worldwide growth in healthcare investments are other reasons that are making the market of transplant rejection prophylaxis broad, further enhancing the segmental growth.

 

Cyclosporine Market, By Dosage Form (2024)

Based on dosage form, the cyclosporine market is categorized into capsule, eye drops, solutions, and creams and ointments. The capsule segment accounted for the highest market share of 31.8% in 2024.
 

  • The capsule form is the most widely used dosage form for patients requiring immunosuppressive treatments. As a result, this segment constitutes a major percentage of the market.
     
  • Capsules are highly compliant for patients, are simple to ingest due to their precision, and are appealing for long term use. The availability of different formulations and strength is boosting the popularity of the capsule segment as well meets patient requirements.
     
  • Furthermore, capsules have a longer shelf life and are easier to store than liquid medication formulations, making them a wiser option for the healthcare professional and the patient.
     
  • Moreover, development of innovative capsule technologies like modified-release capsules for improvement of drug bioavailability and bio-efficacy, further boosts the segmental growth.
     

Based on route of administration, the cyclosporine market is categorized into oral, topical, and parenteral. The oral segment is anticipated to witness high growth to reach USD 5.5 billion by 2034.
 

  • Oral route is the most preferred route, due to its advantages, such as non-invasiveness, patient compliance and convenience of drug administration.
     
  • Oral cyclosporin formulations boost patient compliance during the long-term therapeutic regimen for organ transplant and autoimmune disorders due to ease in administration.
     
  • Furthermore, the introduction of generic oral cyclosporin has aided in the affordability, making it extremely desirable in the market.
     
  • In addition to this, competitors make numerous efforts in ensuring the bioavailability of oral formulations which limits side effects, have further enhanced its share within the market.
     

Based on distribution channel, the cyclosporine market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is anticipated to grow at a CAGR of 14.2% between 2025 – 2034.
 

  • High volume of organ transplant procedures in hospitals increases the demand for cyclosporin in hospital pharmacies thereby increasing the segmental market share.
     
  • Additionally, with the presence of highly skilled professionals, hospital pharmacies provide significant assistance to organ transplant patients with the aid to manage chronic autoimmune diseases.
     
  • In addition, the collaboration of hospital pharmacies with healthcare professionals and manufacturers of pharmaceuticals, further enhances the supply of cyclosporin.

 

U.S. Cyclosporine Market, 2021 – 2034 (USD Billion)

In 2024, the U.S. held a significant position in the North America cyclosporine market and was valued at USD 1.1 billion.
 

  • The availability of high-quality cyclosporine formulations in the U.S. market, ensured by the presence of leading companies and a strong regulatory environment, strengthens the U.S. position in the market.  
     
  • Another prominent reason for the strong hold of the U.S. is the increasing awareness and diagnoses of various autoimmune diseases, including but not limited to rheumatoid arthritis, psoriasis, and Crohn's disease. In the U.S., approximately 1.3 million adults suffer from RA, representing 0.6% to 1% of the adult population, which increases the demand for cyclosporin formulations, thereby enhancing the market growth. 
     

Germany shows strong growth potential in the cyclosporine market.
 

  • Germany’s elaborate healthcare infrastructure and pharmaceutical manufacturing arms, contribute to Germany being one of the significant players in the Europe market.
     
  • Moreover, Germany’s increasing number of elderly citizens and organ transplantations in addition to autoimmune diseases raises the need for cyclosporine and other immunosuppressive therapies. 
     

The cyclosporine market in Asia Pacific is estimated to grow at a CAGR of 15% over the next few years.
 

  • The increasing prevalence of autoimmune diseases and the rise in organ transplantation procedures in the region have propels the regional market growth.
     
  • Countries such as India, Japan, and China lead the pack due to their improved healthcare infrastructure and the increasing availability of advanced medical technology.
     
  • Furthermore, undertakings by the government to improve the medical system and the growing patient population assist in the formation of a substantial market in this region.
     
  • Both domestic and foreign companies are also highly investing in the region due to the growing demand for cyclosporin-based products.
     

India presents significant growth potential in the cyclosporine market.
 

  • India showcases enormous growth potential in the market especially with the growing cases of autoimmune related diseases, increasing transplant procedures performed, and the greater influx of patients requiring treatment with immunosuppressive drugs.
     
  • With the efforts of the Government of India, the total number of organ transplants done per year in the country has increased from 4,990 in the year 2013 to 18,378 in the year 2023. Thus, there is a large demand side opportunity with the number of people requiring long term immunosuppressive treatment like organ transplant patients increasing significantly over the years. 
     
  • As a result of the initiatives undertaken by the Government of India, the number of organ transplants performed in the country each year has grown from 4,990 in 2013 to 18,378 in 2023. Thus, there is a large demand side opportunity with the number of people requiring long term immunosuppressive treatment over the years. 
     
  • Furthermore, India’s capability in producing generic cyclosporine at very affordable rates increases India’s share in the local and international markets, driving growth in the markets. 
     

Brazil cyclosporine market is projected to witness growth in coming years.
 

  • The combination of the country’s massive patient pool and improving accessibility to medical services and therapies is inducing the traction of immunosuppressive treatments like cyclosporine.
     
  • Moreover, the government’s initiatives to strengthen the healthcare system and the regulatory framework encourages pharmaceutical enterprises, further contributing to the market growth.
     

Cyclosporine Market Share

The market is very competitive with both global as well as regional and local players operating in the market. Major firms in this market, such as Novartis, AbbVie, and Apotex, hold a dominant market share with their extensive product offerings and strong distribution networks. These firms together have a strong presence in the global market spanning over a hundred countries across the world. They manage to distribute cyclosporin products across both emerging and already developed markets with the help of strong supply chains. Further, these players enhance their market reach with strategic growth initiatives such as partnerships, acquisitions, and distribution agreements.
 

Additionally, new entrants and other smaller pharmaceutical companies are now coming up with innovative dosages and combination therapies to strengthen their market shares. This is further fueled by increasing cases of autoimmune diseases and organ transplants which motivates the companies to expand their reach. Companies use gaining regulatory approvals and geographic expansion as ways to strategically strengthen their position in this ever-changing market.
 

Cyclosporine Market Companies

Few of the prominent players operating in the cyclosporine industry include:

  • Avet Pharmaceuticals
  • AdvaCare Pharma
  • AbbVie
  • Apotex
  • Cipla
  • Dr. Reddy's Laboratories
  • Novartis
  • Santen Pharmaceutical
  • Sun Pharmaceutical Industries
  • Strides Pharma Science Limited
  • Teva Pharmaceutical Industries
  • Viatris
     

USP’s of top players

  • Significant investments in research and development enable the creation of advanced cyclosporin formulations and delivery systems, tailored to specific therapeutic needs such as organ transplants, autoimmune conditions, and ophthalmology.
     
  • Regulatory compliance and manufacturing capabilities that meet global standards, including FDA and EU regulations.
     
  • Investments in advanced technologies for enhanced bioavailability and efficacy.
     

Cyclosporine Industry News

  • In August 2022, Strides Pharma Science Limited received approval from the U.S. Food and Drug Administration (USFDA) for its Cyclosporine Softgel Capsules USP, available in 25 mg, 50 mg, and 100 mg dosages. This marks a significant milestone as Strides is the first Indian company to gain approval for this product, enhancing its immunosuppressant portfolio in the US market.
     

The cyclosporine market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Market, By Indication

  • Transplant rejection prophylaxis
  • Rheumatoid arthritis
  • Psoriasis
  • Autoimmune myasthenia gravis
  • Dry eye
  • Other indications

Market, By Dosage Form

  • Capsule
  • Eye drops
  • Liquid solutions
  • Creams and ointments

Market, By Route of Administration

  • Oral
  • Topical
  • Parenteral

Market, By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea 
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

 

Authors: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :
Who are some of the prominent players in the cyclosporine industry?
Key players in the market include Avet Pharmaceuticals, AdvaCare Pharma, AbbVie, Apotex, Cipla, Dr. Reddy's Laboratories, Novartis, Santen Pharmaceutical, Sun Pharmaceutical Industries, Strides Pharma Science Limited, Teva Pharmaceutical Industries, and Viatris.
How big is the cyclosporine market?
Why is the transplant rejection prophylaxis segment dominating the market?
What is the size of the U.S. cyclosporine industry?
Cyclosporine Market Scope
  • Cyclosporine Market Size
  • Cyclosporine Market Trends
  • Cyclosporine Market Analysis
  • Cyclosporine Market Share
Related Reports
    Authors: Mariam Faizullabhoy, Gauri Wani
    Buy Now
    $4,123 $4,850
    15% off
    $4,840 $6,050
    20% off
    $5,845 $8,350
    30% off
        Buy now
    Premium Report Details

    Base Year: 2024

    Companies covered: 12

    Tables & Figures: 132

    Countries covered: 19

    Pages: 130

    Download Free PDF

    Top